Form 4: Theravance Biopharma CFO Aziz Sawaf Reports Share Disposal for Tax Obligations
SEC Form 4 Filing
Aziz Sawaf, CFO of Theravance Biopharma, disposed of shares to cover tax obligations related to vesting restricted stock units.
Summary
- On February 20, 2025, Aziz Sawaf, the SVP & Chief Financial Officer of Theravance Biopharma, Inc. (TBPH), disposed of 13,751 ordinary shares.
- The shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
- The transaction was executed at a price of $9.66 per share.
- Following the transaction, Sawaf beneficially owns 299,138 ordinary shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the filing simply reports a routine transaction for tax purposes. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to the market.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of share disposal transaction |
| 02/24/2025 | Date of signature for the Form 4 filing |
Keywords
Theravance Biopharma, Aziz Sawaf, TBPH, Form 4, Share Disposal, Tax Obligations, Restricted Stock Units, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.